A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer
Status: Recruiting
Location: See location...
Intervention Type: Radiation, Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy with IL-2 Followed by Sequential Immunotherapy with CAPOX Combined with PD-1 antibody and IL-2 for Locally Advanced Rectal Cancer
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Males and females aged between 18 and 70 years;
• ECOG (Eastern Cooperative Oncology Group) performance status score of 0 or 1;
• Tumor tissue samples obtained and histologically confirmed as rectal adenocarcinoma;
• Adequate hematological, liver, and kidney functions: neutrophil count ≥ 1.5×10\^9/L; platelet count ≥ 75×10\^9/L; serum total bilirubin ≤ 1.5× upper limit of normal (UNL); aspartate aminotransferase ≤ 2.5× UNL; alanine aminotransferase ≤ 2.5× UNL; serum creatinine ≤ 1.5× UNL.
Locations
Other Locations
China
Jiangsu Province Hospital
RECRUITING
Nanjing
Contact Information
Primary
Yueming Sun
jssym@vip.sina.com
025-68306026
Time Frame
Start Date: 2024-10-05
Estimated Completion Date: 2028-10-31
Participants
Target number of participants: 35
Treatments
Experimental: Experimental group
Experimental arm
Related Therapeutic Areas
Sponsors
Leads: The First Affiliated Hospital with Nanjing Medical University